


WHAT IS CLAIMED IS

1. A phenoxypropylamine compound of the formula (I)



wherein each symbol in the formula means as follows:


5 a bond represented by a solid line and a dotted line shows a double bond or a single bond;

X is a hydrogen atom, a hydroxy group, a C₁-C₈ alkoxy group, an acyloxy group or an oxo group;

provided that when R¹ is a group of the following formula (2),

10 X should not be a hydrogen atom;

R¹ is a group of the following formula



wherein

Y is O or S,

15 Ar is optionally substituted aromatic hydrocarbon,

R² is optionally substituted aryl group or optionally substituted aromatic heterocyclic group,

R⁵ is optionally substituted aryl group or optionally substituted aromatic heterocyclic group,

20 Z is void or -CH₂-, and

R⁶ is hydrogen atom, hydroxy group, acetamido group,

R³ is a hydrogen atom, a C₁-C₁₈ alkyl group or a halogen atom;

25

V is $-\text{CH}_2-$, $-\text{O}-$, $-\text{S}-$ or the formula $-\text{N}(\text{R}^4)-$
 wherein R^4 is hydrogen atom, C_1 - C_{18} alkyl group or
 optionally substituted aralkyl group;




W is void or $-\text{CH}_2-$ or $-\text{C}(=\text{O})-$;

5 R^7 is a C_1 - C_4 hydroxyalkyl group, an acyl group,
 an optionally substituted saturated or unsaturated
 heterocyclic group, an optionally substituted fused
 heterocyclic group, a C_1 - C_4 alkylsulfonyl group or the
 formula $-\text{Q}-\text{R}^9$

10 wherein

Q is $-\text{C}(=\text{O})-$, $-\text{C}(=\text{S})-$, $-\text{CH}_2-$ or $-\text{S}(=\text{O})_2-$, and

R^9 is a group of the following formula



or $-\text{NH}-\text{NH}-\text{R}^{15}$

15 wherein R^{10} and R^{11} are each independently hydrogen
 atom, C_1 - C_{18} alkyl group, optionally substituted
 aryl group, optionally substituted aralkyl group
 or alkoxy group, R^{12} is hydrogen atom, optionally

atom, phenyl group, C_1 - C_4 alkyl group, C_1 - C_2
 halogenated alkyl group, halogen atom, C_2 - C_4

alkenyl group, C₁-C₄ hydroxyalkyl group,
 alkoxyalkyl group, alkyloxycarbonyl group,
 optionally substituted amino group, acetamido
 group, carboxyl group, acyl group, optionally
 5 substituted alkyloxy group, alkylthio group or
 cyano group;
 provided that when R¹ is a group of the above
 formula (2), R⁷ should not be C₁-C₄ hydroxyalkyl
 group or acyl group, and R¹⁰ and R¹¹ are not each
 10 hydrogen atom at the same time; or

R⁷ and W in combination may form a ring of the following
 formula




wherein

15 E is oxygen atom or sulfur atom, and
 Q' is an optionally substituted 4 to 7-membered
 heterocycle having 1 or 2 hetero atom(s) selected
 from the group consisting of nitrogen atom and
 oxygen atom in the ring, in which case V is
 20 hydrogen atom; and

Ra, Rb and Rc are each independently a hydrogen atom, a C₁-C₁₈
 alkyl group, a hydroxy group, a C₁-C₈ alkoxy group,
 a halogen atom, an acyl group, a nitro group or an
 amino group;

25 provided that when R⁷ and W are bonded to form a ring of the
 above formula (14), Ra, Rb and Rc are not each hydroxy group or
 C₁-C₈ alkoxy group;
 an optically active compound thereof, a pharmaceutically

2. The compound of claim 1, which is represented by the formula
 (I)




wherein each symbol in the formula means as follows:

a bond represented by a solid line and a dotted line shows a double bond;

5 X is a hydrogen atom, a hydroxy group, a C₁-C₈ alkoxy group, an acyloxy group or an oxo group;

R¹ is a group of the following formula



wherein

10 Y is O or S,

Ar is optionally substituted benzene or naphthalene,

R² is optionally substituted aryl group or optionally substituted aromatic heterocyclic group,

15 R⁵ is optionally substituted aryl group or optionally substituted aromatic heterocyclic group,

Z is void or -CH₂-, and

R⁶ is hydrogen atom, hydroxy group, acetamido group, carboxyl group, alkoxycarbonyl group, cyano group or C₁-C₈ alkoxy group;

20 R³ is a hydrogen atom, a C₁-C₁₈ alkyl group or a halogen atom;

R⁴ is a hydrogen atom, a C₁-C₁₈ alkyl group or a halogen atom;

optionally substituted alkyl group;




25 W is void or -CH₂- or -C(=O)-;

R^7 is a C_1 - C_4 hydroxyalkyl group, an acyl group,
 an optionally substituted saturated or unsaturated
 heterocyclic group, an optionally substituted fused
 heterocyclic group, a C_1 - C_4 alkylsulfonyl group or the
 formula $-Q-R^9$

wherein

Q is $-C(=O)-$, $-C(=S)-$, $-CH_2-$ or $-S(=O)_2-$, and

R^9 is a group of the following formula



or $-NH-NH-R^{15}$
 wherein R^{10} and R^{11} are each independently hydrogen
 atom, C_1 - C_{18} alkyl group, optionally substituted
 aryl group, optionally substituted aralkyl group
 or alkoxy group, R^{12} is hydrogen atom, optionally
 substituted aryl group, C_1 - C_{18} alkyl group, C_1 - C_8
 alkoxy group or acyl group, and R^{15} is hydrogen
 atom, phenyl group, C_1 - C_4 alkyl group, C_1 - C_2

alkoxyalkyl group, alkyloxycarbonyl group,
 optionally substituted amino group, acetamido

group, carboxyl group, acyl group, optionally substituted alkyloxy group, alkylthio group or cyano group; and

Ra, Rb and Rc are each independently a hydrogen atom, a C₁-C₁₈ alkyl group, a hydroxy group, a C₁-C₈ alkoxy group, a halogen atom, an acyl group, a nitro group or an amino group;


provided that when R¹ is a group of the above formula (2), R⁷ should not be C₁-C₄ hydroxyalkyl group or acyl group, and R¹⁰ and R¹¹ are not each hydrogen atom at the same time; an optically active compound thereof, a pharmaceutically acceptable salt thereof or a hydrate thereof.

3. The compound of claim 2, which is represented by the formula (I) wherein each symbol in the formula means as follows:

a bond represented by a solid line and a dotted line shows a double bond;

X is a hydroxy group;

R¹ is a group of the following formula



wherein

R⁵ is optionally substituted phenyl group or naphthyl group,

Z is void, and


R⁶ is hydrogen atom;

R³ is a hydrogen atom or a C₁-C₄ alkyl group;


V is -CH₂-, -O-, -S- or -N(R⁴)-

W is void;


R⁷ is a group of the following formula




(15)



(16)



(17)




(18)

or the formula $-\text{CO}-\text{R}^9$


wherein

R^8 is hydrogen atom, phenyl group, C_1 - C_4 alkyl group, C_1 - C_2 halogenated alkyl group, halogen atom, C_2 - C_4 alkenyl group, C_1 - C_4 hydroxyalkyl group, alkoxyalkyl group, alkyloxycarbonyl group, optionally substituted amino group, acetamido group, carboxyl group, acyl group, optionally substituted alkyloxy group, alkylthio group or cyano group, and


R^9 is a group of the following formula




(5)




(6)



(7)



(8)



(9)

or




(10)

wherein R^{10} and R^{11} are each independently hydrogen atom, C_1 - C_{18} alkyl group, optionally substituted aryl group, optionally substituted aralkyl group or alkoxy group, and R^{12} is hydrogen atom, optionally substituted aryl group, C_1 - C_{18} alkyl group, C_1 - C_8 alkoxy group or acyl group; and

Ra , Rb and Rc are each a hydrogen atom;

4. The compound of claim 2 or claim 3, which is represented by

the formula (I')




wherein each symbol is as in claim 2,
an optically active compound thereof, a pharmaceutically
5 acceptable salt thereof or a hydrate thereof.

5. The compound of claim 2, which is selected from the group consisting of

- (1) 1-(4-(2-hydroxy-3-(4-(naphthalen-2-yl)piperidino)-
propyloxy)benzo(b)furan-2-ylcarbonyl)pyrrolidine,
(2) 4-(4-(2-hydroxy-3-(4-(naphthalen-2-yl)piperidino)-
propyloxy)benzo(b)furan-2-ylcarbonyl)morpholine,
(4) 4-(2-hydroxy-3-(4-(naphthalen-2-yl)piperidino)propyloxy)-
N,N-dimethylbenzo(b)furan-2-carboxamide,
(12) 1-(4-(2-hydroxy-3-(4-(naphthalen-2-yl)piperidino)-
propyloxy)benzo(b)thiophen-2-ylcarbonyl)pyrrolidine,
(13) 4-(4-(2-hydroxy-3-(4-(naphthalen-2-yl)piperidino)-
propyloxy)benzo(b)thiophen-2-ylcarbonyl)morpholine,
(15) 4-(2-hydroxy-3-(4-(naphthalen-1-yl)piperidino)propyloxy)-
N,N-dimethylbenzo(b)thiophene-2-carboxamide,
(17) 4-(2-hydroxy-3-(4-(naphthalen-2-yl)piperidino)propyloxy)-
N,N-dimethylbenzo(b)thiophene-2-carboxamide,
(20) 4-(7-(2-hydroxy-3-(4-(naphthalen-2-yl)piperidino)-
propyloxy)benzo(b)furan-2-ylcarbonyl)morpholine,
(21) 7-(2-hydroxy-3-(4-(naphthalen-2-yl)piperidino)propyloxy)-
N,N-dimethylbenzo(b)furan-2-carboxamide,
(27) 4-(2-hydroxy-3-(4-(naphthalen-2-yl)piperidino)propyloxy)-
N,N-dimethyl-1-methylindole-2-carboxamide,
(30) 4-(2-hydroxy-3-(4-(naphthalen-2-yl)piperidino)propyloxy)-
N,N-dimethyl-1-methylindole-2-carboxamide,

- (35) 1-(2-(5-methyl-1,2,4-oxadiazol-3-yl)benzo(b)furan-4-yloxy)-3-(4-(naphthalen-2-yl)piperidino)-2-propanol,
 (37) 1-(2-(5-methyl-1,3,4-oxadiazol-2-yl)benzo(b)furan-4-yloxy)-3-(4-(naphthalen-2-yl)piperidino)-2-propanol,
 5 (38) 1-(2-(5-trifluoromethyl-1,3,4-oxadiazol-2-yl)benzo(b)furan-4-yloxy)-3-(4-(naphthalen-2-yl)piperidino)-2-propanol,
 (39) 1-(2-(5-methyl-1,3,4-oxadiazol-2-yl)benzo(b)furan-7-yloxy)-3-(4-(naphthalen-2-yl)piperidino)-2-propanol,
 10 (42) 1-(2-(5-methyl-1,3,4-oxadiazol-2-yl)-1H-indole-4-yloxy)-3-(4-(naphthalen-2-yl)piperidino)-2-propanol,
 (44) 1-(2-(3-methyl-1,2,4-oxadiazol-5-yl)benzo(b)furan-4-yloxy)-3-(4-(naphthalen-2-yl)piperidino)-2-propanol,
 (48) 1-(2-(5-methyloxazol-2-yl)benzo(b)furan-7-yloxy)-3-(4-(naphthalen-2-yl)piperidino)-2-propanol,
 15 (81) 3-(4-(3,4-dichlorophenyl)piperidino)-1-(2-(5-methyloxazol-2-yl)benzo(b)furan-4-yloxy)-2-propanol,
 (88) 1-(4-(3,4-dichlorophenyl)piperidino)-3-(2-(5-methyl-1,3,4-oxadiazol-2-yl)benzo(b)furan-4-yloxy)-2-propanol, and
 20 (93) 3-(4-(3,4-dimethylphenyl)piperidino)-1-(2-(5-ethyl-1,3,4-oxadiazol-2-yl)benzo(b)furan-4-yloxy)-2-propanol,
 an optically active compound thereof, a pharmaceutically acceptable salt thereof or a hydrate thereof.

- 25 6. The compound of claim 1, which is represented by the formula (I)



wherein each symbol is as defined in the following:



— is a bond,

— is a double bond or a single bond,


X is a hydrogen atom, a hydroxy group, a C₁-C₈ alkoxy

group or an acyloxy group;

R¹ is a group of the following formula



or



wherein

5 R² is optionally substituted aryl group or optionally substituted aromatic heterocyclic group,

R⁵ is optionally substituted aryl group or optionally substituted aromatic heterocyclic group,

Z is void or -CH₂-, and

10 R⁶ is hydrogen atom, hydroxy group or C₁-C₈ alkoxy group;

R³ is a hydrogen atom, a C₁-C₁₈ alkyl group or a halogen atom;

R⁷ and W are bonded to form a ring of the following formula



15 wherein

E is an oxygen atom or a sulfur atom, and

Q' is an optionally substituted 4 to 7-membered heterocycle having 1 or 2 hetero atom(s) selected from the group consisting of nitrogen atom and oxygen atom in the ring,

and V is hydrogen atom; and

Ra, Rb and Rc are each independently a hydrogen atom, a C₁-C₁₈ alkyl group, a halogen atom, an acyl group, a nitro group or an amino group;

25 an optically active compound thereof, a pharmaceutically acceptable salt thereof, a hydrate thereof,




the compound of claim 6, which is represented by the formula (I) wherein each symbol in the formula means as

follows:


a group of the following formula



is a group of the following formula



or



5

wherein

E is an oxygen atom or a sulfur atom,

q is 0, 1, 2 or 3,

R^{4'}, R^{7'} and R^{8'} are each independently a hydrogen atom, a C₁-C₁₈

10

alkyl group, an optionally substituted aryl group or

an optionally substituted aralkyl group, and

other symbols are as defined in claim 6,

an optically active compound thereof, a pharmaceutically

acceptable salt thereof or a hydrate thereof.

15

8. The compound of claim 6, which is represented by the formula (I) wherein each symbol in the formula means as follows:



a bond represented by a solid line and a dotted line shows a

20

double bond;

X is a hydroxy group;

R¹ is a group of the following formula



wherein


25

R⁵ is optionally substituted phenyl group or naphthyl

group,
 Z is void, and
 R⁶ is hydrogen atom;
 R³ is a hydrogen atom or a C₁-C₄ alkyl group;
 5 a group of the following formula




is a group of the following formula



wherein q is 1 and R^{4'} is hydrogen atom or C₁-C₄ alkyl
 10 group; and

Ra, Rb and Rc are each a hydrogen atom;
 an optically active compound thereof, a pharmaceutically
 acceptable salt thereof or a hydrate thereof.

15 9. The compound of claim 6, which is represented by the formula
 (I'')



wherein each symbol is as as defined in claim 6,
 an optically active compound thereof, a pharmaceutically
 20 acceptable salt thereof or a hydrate thereof.

consisting of

(306) 5-(2'-(2-hydroxy-3-(4-(naphthalen-2-yl)piperidino)-

propyloxy)benzylidene)-1,3-dimethylimidazolidine-2,4-dione,
 (307) α -(2'-(2-hydroxy-3-(4-(naphthalen-2-yl)piperidino)-
 propyloxy)benzylidene)- γ -butyrolactone,
 (308) α -(2'-(2-hydroxy-3-(4-(naphthalen-2-yl)piperidino)-
 5 propyloxy)benzylidene)- γ -butyrolactone,
 (309) α -(2'-(2-hydroxy-3-(4-(naphthalen-2-yl)piperidino)-
 propyloxy)benzylidene)- γ -butyrolactone,
 (310) α -(2'-(3-(4-(3-fluoro-4-methylphenyl)piperidino)-2-
 hydroxypropyloxy)benzylidene)- γ -butyrolactone,
 10 (311) α -(2'-(3-(4-(3,4-dimethylphenyl)piperidino)-2-
 hydroxypropyloxy)benzylidene)- γ -butyrolactone,
 (312) α -(2'-(3-(4-(4-chloro-3-fluorophenyl)piperidino)-2-
 hydroxypropyloxy)benzylidene)- γ -butyrolactone,
 (313) α -(2'-(3-(4-(4-chloro-3-trifluoromethylphenyl)-
 15 piperidino)-2-hydroxypropyloxy)benzylidene)- γ -butyrolactone,
 (314) α -(2'-(2-hydroxy-3-(4-(naphthalen-1-yl)piperidino)-
 propyloxy)benzylidene)- γ -butyrolactone,
 (315) α -(2'-(2-hydroxy-3-(4-(naphthalen-2-yl)piperidino)-
 propyloxy)benzylidene)- δ -valerolactone,
 20 (316) α -(2'-(2-hydroxy-3-(4-(naphthalen-2-yl)piperidino)-
 propyloxy)benzylidene)- γ -valerolactone,
 (319) 3-(2'-(2-hydroxy-3-(4-(naphthalen-2-yl)piperidino)-
 propyloxy)benzylidene)-2-pyrrolidone,
 (322) 3-(2'-(2-hydroxy-3-(4-(naphthalen-2-yl)piperidino)-
 25 propyloxy)benzylidene)-1-methyl-2-pyrrolidone, and
 (325) α -(2'-(2-hydroxy-3-(4-(6-methoxynaphthalen-2-
 yl)piperidino)propyloxy)benzylidene)- γ -butyrolactone,
 an optically active compound thereof, a pharmaceutically
 acceptable salt thereof or a hydrate thereof.

30

11. A pharmaceutical agent comprising a compound of the formula
 (317) α -(2'-(2-hydroxy-3-(4-(naphthalen-2-yl)piperidino)-
 propyloxy)benzylidene)- γ -butyrolactone,
 an optically active compound thereof, a pharmaceutically
 acceptable salt thereof or a hydrate thereof.

12. The pharmaceutical agent of claim 11, which is an agent for the treatment of depression.


13. A pharmaceutical composition comprising at least one member
5 selected from the group consisting of a compound of claim 1, an optically active compound thereof, a pharmaceutically acceptable salt thereof and a hydrate thereof, and a pharmaceutically acceptable carrier.

10 14. The pharmaceutical composition of claim 13, which is an agent for the treatment of depression.

15 15. A 5HT_{1A} antagonist having a selective serotonin reuptake inhibitory action, which comprises a compound of claim 1, an optically active compound thereof, a pharmaceutically acceptable salt thereof or a hydrate thereof.

16. A selective serotonin reuptake inhibitor having a 5HT_{1A} antagonistic action, which comprises a compound of claim 1, an
20 optically active compound thereof, a pharmaceutically acceptable salt thereof or a hydrate thereof.


17. A compound of the formula (II)



25 wherein each symbol in the formula means as follows:

X is a hydrogen atom, a hydroxy group, a C₁-C₄ alkyl group

or a group of the following formula



wherein

- Y is O or S,
- Ar is optionally substituted benzene or naphthalene,
- R² is optionally substituted aryl group or optionally substituted aromatic heterocyclic group,
- R⁵ is optionally substituted aryl group or optionally substituted aromatic heterocyclic group,
- Z is void or -CH₂, and
- R⁶ is hydrogen atom, hydroxy group, acetamido group, carboxyl group, alkoxycarbonyl group, cyano group or C₁-C₈ alkoxy group, provided that when V is -N(R⁴)-, R⁶ should not be hydroxy group;

R³ is a hydrogen atom, a C₁-C₁₈ alkyl group or a halogen atom;

V is -CH₂-, -O-, -S- or the formula -N(R⁴)-

wherein

R⁴ is hydrogen atom, C₁-C₁₈ alkyl group or optionally substituted aralkyl group;


W is void, -CH₂- or -C(=O)-;

R¹⁴ is a hydrogen atom or a C₁-C₄ alkyl; and

Ra, Rb and Rc are each independently a hydrogen atom, a C₁-C₁₈ alkyl group, a hydroxy group, a C₁-C₈ alkoxy group, a halogen atom, an acyl group, a nitro group or an amino group;

an optically active compound thereof; a pharmaceutically

18. A compound of the formula (III)



(III)

wherein each symbol is as follows:

R is an allyl group or a 2,3-epoxypropan-1-yl group;
a bond represented by a solid line and a dotted line shows a
5 double bond or a single bond;

E is an oxygen atom or a sulfur atom;


R³ is a hydrogen atom, a C₁-C₁₈ alkyl group or a halogen
atom;

Q' is an optionally substituted 4 to 7-membered
10 heterocycle having 1 or 2 hetero atom(s) selected from
the group consisting of nitrogen atom and oxygen atom
in the ring; and

Ra, Rb and Rc are each independently a hydrogen atom, a C₁-C₁₈
alkyl group, a hydroxy group, a C₁-C₈ alkoxy group, a
15 halogen atom, an acyl group, a nitro group or an amino
group;


an optically active compound thereof, a pharmaceutically
acceptable salt thereof or a hydrate thereof.

20 19. The compound of claim 18, wherein, in the formula (III),
each symbol is as follows:
the group of the following formula




(14)


is a group of the following formula




(19)



(20)



(21)



(22)

wherein

E is oxygen atom or sulfur atom,

q is 0, 1, 2 or 3,

5 R^{4'}, R^{7'} and R^{8'} are each independently hydrogen atom, C₁-C₁₈ alkyl group, optionally substituted aryl group or optionally substituted aralkyl group, and

other symbols are as defined in claim 18,

an optically active compound thereof, a pharmaceutically
10 acceptable salt thereof or a hydrate thereof.

20. A compound selected from the group consisting of
2-(4-methoxybenzo(b) furan-2-yl)-5-methyl-1,3,4-oxadiazole,
2-(4-hydroxybenzo(b) furan-2-yl)-5-methyl-1,3,4-oxadiazole,
15 (S)-2-(4-glycidyloxybenzo(b) furan-2-yl)-5-methyl-1,3,4-oxadiazole,
2-(7-methoxybenzo(b) furan-2-yl)-5-methyl-1,3,4-oxadiazole,
2-(4-(methoxymethyloxy) benzo(b) thiophen-2-yl)-5-methyl-1,3,4-oxadiazole,
20 2-(4-hydroxybenzo(b) thiophen-2-yl)-5-methyl-1,3,4-oxadiazole,
4-benzyloxy-2-(5-methyl-1,3,4-oxadiazol-2-yl)-1H-indole,
2-(7-methoxybenzo(b) furan-2-yl)-5-phenyl-1,3,4-oxadiazole,
2-(4-methoxybenzo(b) furan-2-yl)-5-trifluoromethyl-1,3,4-oxadiazole,
25 2-(4-hydroxybenzo(b) furan-2-yl)-5-trifluoromethyl-1,3,4-oxadiazole

, 1,3,4-oxadiazole,

2-(7-methoxybenzo(b) furan-2-yl)-5-trifluoromethyl-1,3,4-

oxadiazole,
 2-(7-hydroxybenzo(b) furan-2-yl)-5-trifluoromethyl-1,3,4-
 oxadiazole,
 (S)-2-(7-glycidyloxybenzo(b) furan-2-yl)-5-trifluoromethyl-
 5 1,3,4-oxadiazole,
 N'-(4-methoxybenzo(b) furan-2-ylcarbonyl)propionohydrazide,
 2-(4-methoxybenzo(b) furan-2-yl)-5-ethyl-1,3,4-oxadiazole,
 2-(4-hydroxybenzo(b) furan-2-yl)-5-ethyl-1,3,4-oxadiazole,
 (S)-2-(4-glycidyloxybenzo(b) furan-2-yl)-5-ethyl-1,3,4-
 10 oxadiazole,
 2-(4-methoxybenzo(b) furan-2-yl)-5-methyl-1,3,4-thiadiazole,
 2-(4-hydroxybenzo(b) furan-2-yl)-5-methyl-1,3,4-thiadiazole,
 (S)-2-(4-glycidyloxybenzo(b) furan-2-yl)-5-methyl-1,3,4-
 thiadiazole,
 15 5-ethoxycarbonyl-2-(4-methoxybenzo(b) furan-2-yl)-1,3,4-
 oxadiazole,
 5-ethoxycarbonyl-2-(4-hydroxybenzo(b) furan-2-yl)-1,3,4-
 oxadiazole,
 5-(4-(methoxymethyloxy) benzo(b) furan-2-yl)-2,3-dihydro-1,3,4-
 20 oxadiazole-2-thione,
 5-(4-(methoxymethyloxy) benzo(b) furan-2-yl)-2-methylthio-1,3,4-
 oxadiazole,
 5-(4-hydroxybenzo(b) furan-2-yl)-2-methylthio-1,3,4-oxadiazole,
 5-(4-(methoxymethyloxy) benzo(b) furan-2-yl)-2,3-dihydro-1,3,4-
 25 oxadiazol-2-one,
 5-(4-(methoxymethyloxy) benzo(b) furan-2-yl)-2-methoxy-1,3,4-
 oxadiazole,
 (S)-5-(4-glycidyloxybenzo(b) furan-2-yl)-2-methoxy-1,3,4-
 oxadiazole,
 30 2-ethoxy-5-(4-(methoxymethyloxy) benzo(b) furan-2-yl)-1,3,4-
 oxadiazole,
 oxadiazole,
 2-(1-methylethyloxy)-5-(4-(methoxymethyloxy) benzo(b) furan-2-

yl)-1,3,4-oxadiazole and

(S)-2-(1-methylethyloxy)-5-(4-glycidyloxybenzo(b) furan-2-yl)-
1,3,4-oxadiazole.